Biomarkers for Huntington's disease: an update

Bibliography

• Tabrizi SJ, Langbehn DR, Leavitt BR, Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8(9):791-801
   PubMed Web of Science ®Google Scholar
• Paulsen JS, Langbehn DR, Stout JC, Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008;79(8):874-80
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Scahill RI, Durr A, Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10(1):31-42
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Reilmann R, Roos RA, Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11(1):42-53
   PubMed Web of Science ®Google Scholar
• Weaver KE, Richards TL, Liang O, Longitudinal diffusion tensor imaging in Huntington's disease. Exp Neurol 2009;216(2):525-9
   PubMed Web of Science ®Google Scholar
• Sritharan A, Egan GF, Johnston L, A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J Neurol Neurosurg Psychiatry 2010;81(3):257-62
   PubMed Web of Science ®Google Scholar
• Kloppel S, Draganski B, Siebner HR, Functional compensation of motor function in pre-symptomatic Huntington's disease. Brain 2009;132(Pt 6):1624-32
   PubMed Web of Science ®Google Scholar
• Wolf RC, Sambataro F, Vasic N, Longitudinal functional magnetic resonance imaging of cognition in preclinical Huntington's disease. Exp Neurol 2011;231(2):214-22
   PubMed Web of Science ®Google Scholar
• Schippling S, Schneider SA, Bhatia KP, Abnormal motor cortex excitability in preclinical and very early Huntington's disease. Biol Psychiatry 2009;65(11):959-65
   PubMed Web of Science ®Google Scholar
• Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington's disease. Lancet Neurol 2011;10(6):573-90
   PubMed Web of Science ®Google Scholar
• Rowe KC, Paulsen JS, Langbehn DR, Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology 2010;24(4):435-42
   PubMed Web of Science ®Google Scholar
• Beglinger LJ, Duff K, Allison J, Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status. J Clin Exp Neuropsychol 2010;32(6):573-8
   PubMed Web of Science ®Google Scholar
• Leoni V, Mariotti C, Tabrizi SJ, Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 2008;131(Pt 11):2851-9
   PubMed Web of Science ®Google Scholar
• Hu Y, Chopra V, Chopra R, Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci USA 2011;108(41):17141-6
   PubMed Web of Science ®Google Scholar
• Dalrymple A, Wild EJ, Joubert R, Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 2007;6(7):2833-40
   PubMed Web of Science ®Google Scholar
• Hardy J, Guerreiro R, Lovestone S. Clusterin as an Alzheimer biomarker. Arch Neurol 2011;68(11):1459-60
   PubMedGoogle Scholar
• Weiss A, Klein C, Woodman B, Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J Neurochem 2008;104(3):846-58
   PubMed Web of Science ®Google Scholar
• Weiss A, Abramowski D, Bibel M, Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal Biochem 2009;395(1):8-15
   PubMed Web of Science ®Google Scholar
• Fang Q, Strand A, Law W, Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol Cell Proteomics 2009;8(3):451-66
   PubMed Web of Science ®Google Scholar
• Constantinescu R, Romer M, Zetterberg H, Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease. Parkinsonism Relat Disord 2011;17(9):714-15
   PubMed Web of Science ®Google Scholar
• Baker K, Queller S, Clough MJ, The Huntington's disease (HD) Toolkit Project; using meta-analysis to identify cognitive tests for use in clinical trials. Clinical Genetics 2011. 80-S1), 47
   Google Scholar
• Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6(3):131-44
   PubMed Web of Science ®Google Scholar